Journal of Nuclear Medicine · 2017 · 46 citations · 40 references
MedicineNuclear MedicineRadiologyDiagnostic ImagingDiagnostic RadiologyMolecular ImagingBreast Cancer ImagingBreast ImagingEndocrine ImagingOncologic Nuclear ImagingPositron Emission TomographyTumor Imaging16 Alpha-fluoro-17 Beta-estradiol ImagingBreast Positron Emission TomographyEndocrine Pet ImagingHormone Receptor-positive Breast Cancer TherapyOncologic Pet ImagingPet QuantificationPhase Ii Clinical Trials
After encouraging preclinical and human dosimetry results for the novel estrogen receptor (ER) PET radiotracer 4-fluoro-11β-methoxy-16α-<sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-4FMFES), a phase II clinical trial was initiated to compare the PET imaging diagnostic potential of <sup>18</sup>F-4FMFES with that of 16α-<sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-FES) in ER-positive (ER+) breast cancer patients. <b>Methods:</b> Patients diagnosed with ER+ breast cancer (<i>n</i> = 31) were recruited for this study, including 6 who underwent mastectomy or axillary node dissection. For each patient, <sup>18</sup>F-FES and <sup>18</sup>F-4FMFES PET/CT scans were done sequentially (within a week) and in random order. One hour after injection of either radiotracer, a head-to-thigh static scan with a 2-min acquisition per bed position was obtained. Blood samples were taken at different times after injection to assess each tracer metabolism by reverse-phase thin-layer chromatography. The SUV<sub>mean</sub> of nonspecific tissues and the SUV<sub>max</sub> of the tumor were evaluated for each detected lesion, and tumor-to-nonspecific organ ratios were calculated. <b>Results:</b> Blood metabolite analysis 60 min after injection of the tracer showed a 2.5-fold increase in metabolic stability of <sup>18</sup>F-4FMFES over <sup>18</sup>F-FES. Although for most foci <sup>18</sup>F-4FMFES PET had an SUV<sub>max</sub> similar to that of <sup>18</sup>F-FES PET, tumor contrast improved substantially in all cases. Lower uptake was consistently observed in nonspecific tissues for <sup>18</sup>F-4FMFES, notably a 4-fold decrease in blood-pool activity as compared with <sup>18</sup>F-FES. Consequently, image quality was considerably improved using <sup>18</sup>F-4FMFES, with lower overall background activity. As a result, <sup>18</sup>F-4FMFES successfully identified 9 more lesions than <sup>18</sup>F-FES. <b>Conclusion:</b> This phase II study with ER+ breast cancer patients showed that <sup>18</sup>F-4FMFES PET achieves a lower nonspecific signal and better tumor contrast than <sup>18</sup>F-FES PET, resulting in improved diagnostic confidence and lower false-negative diagnoses.
40
Linda S. Lindström, Eva Karlsson, Ulla Wilking et al. · Journal of Clinical Oncology · 2012 · 535 citations
Maya Gutierrez, Simone Detre, Stephen Johnston et al. · Journal of Clinical Oncology · 2005 · 489 citations · Full text
Medicine, Cancer Biology, Oncology +15
Breast cancer: PET imaging of estrogen receptors.
Mark A. Mintun, M. J. Welch, Barry A. Siegel et al. · Radiology · 1988 · 417 citations
Medicine, Nuclear Medicine, Oncology +17